🔗 Share this article World Health Organization Sounds Concern Over Severe Scarcity of Weight-Loss Medications Less than one in 10 people that would benefit from GLP-1 drugs including Wegovy can access them, states the global health agency as it releases its inaugural guidance on the drugs. Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer access to these injectable treatments. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our latest guidance acknowledges that obesity is a long-term condition that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major barriers to broad availability to the jabs that can aid individuals in losing considerable body mass, explains the body. GLP-1 Therapy Supply Crisis Even under the current most favorable case, the supply of such drugs might only reach around 100 million people – under 10% of the global need, per the WHO. The advice encourages nations and manufacturers to expand access, via strategies such as patent sharing. Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Function The injections mimick a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so users consume fewer calories. Patients usually see weight reduction in the initial weeks of starting on the regular doses. Studies suggests patients may put most of the weight back on after a year of stopping the medication, because their typical food cravings return. To be carrying excess weight elevates your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
Less than one in 10 people that would benefit from GLP-1 drugs including Wegovy can access them, states the global health agency as it releases its inaugural guidance on the drugs. Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer access to these injectable treatments. According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our latest guidance acknowledges that obesity is a long-term condition that can be managed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major barriers to broad availability to the jabs that can aid individuals in losing considerable body mass, explains the body. GLP-1 Therapy Supply Crisis Even under the current most favorable case, the supply of such drugs might only reach around 100 million people – under 10% of the global need, per the WHO. The advice encourages nations and manufacturers to expand access, via strategies such as patent sharing. Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026. The Way Weight-Loss Injections Function The injections mimick a body's own hormone to slow digestion, reduce hunger and increase feelings of fullness so users consume fewer calories. Patients usually see weight reduction in the initial weeks of starting on the regular doses. Studies suggests patients may put most of the weight back on after a year of stopping the medication, because their typical food cravings return. To be carrying excess weight elevates your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers. Obesity impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.